Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway
Aims: To investigate the potential protective role of montelukast (Mont) in the pre-eclampsia rat model induced by L-NG-Nitro arginine methyl ester (L-NAME). Methods and materials: Thirty-two pregnant female albino Wistar rats were assigned to four groups: the control group: pregnant rats received v...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/8/914 |
| _version_ | 1797442836649476096 |
|---|---|
| author | Walaa Yehia Abdelzaher Gomaa Mostafa-Hedeab Haitham Ahmed Bahaa Ahmad Mahran Michael Atef Fawzy Sara Mohamed Naguib Abdel Hafez Nermeen N. Welson Remon Roshdy Rofaeil |
| author_facet | Walaa Yehia Abdelzaher Gomaa Mostafa-Hedeab Haitham Ahmed Bahaa Ahmad Mahran Michael Atef Fawzy Sara Mohamed Naguib Abdel Hafez Nermeen N. Welson Remon Roshdy Rofaeil |
| author_sort | Walaa Yehia Abdelzaher |
| collection | DOAJ |
| description | Aims: To investigate the potential protective role of montelukast (Mont) in the pre-eclampsia rat model induced by L-NG-Nitro arginine methyl ester (L-NAME). Methods and materials: Thirty-two pregnant female albino Wistar rats were assigned to four groups: the control group: pregnant rats received vehicles; the Mont group: pregnant rats received Mont (10 mg/kg/day, p.o.) from the 6th to the 18th day of gestation; the L-NAME group: pregnant rats received L-NAME (50 mg/kg/day, i.p.) from the 9th to the 18th day of gestation; the Mont/L-NAME group: pregnant rats received Mont (10 mg/kg/day, p.o.) from the 6th to the 18th day of gestation and L-NAME (50 mg/kg/day, i.p.) from the 9th to the 18th day of gestation. Placental, hepatic, and renal malondialdehyde (MDA), total nitrites (NOx), interleukin 6 (IL-6), and tumor necrosis factor (TNF)-α were determined. Serum alanine transaminase (ALT), aspartate transaminase (AST), creatinine, urea, 24-h urinary protein, and the placental growth factor (PGF) were measured. Histopathological examinations of the placental, hepatic, and renal tissues were also performed. In addition, placental, hepatic, and renal Janus kinase 2 (Jak2) and signal transducer and activator of transcription 3 (STAT3) immunoblotting were performed. Key findings: Mont improves oxidative stress, IL-6, TNF-α, ALT, AST, creatinine, urea, 24-h urinary protein, PGF, Jak2, and STAT3 which were all affected by L-NAME. Moreover, the histopathological assessment indicated that Mont restored the normal architecture that was markedly disturbed by L-NAME. Significance: Mont exerted the biochemical and histopathological amelioration of L-NAME-caused pre-eclampsia through its anti-inflammatory, anti-oxidant function and suppression of the IL-6/Jak2/STAT3 signaling pathway. |
| first_indexed | 2024-03-09T12:47:56Z |
| format | Article |
| id | doaj.art-52283607dad74062a45745bbb008dc52 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T12:47:56Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-52283607dad74062a45745bbb008dc522023-11-30T22:09:50ZengMDPI AGPharmaceuticals1424-82472022-07-0115891410.3390/ph15080914Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling PathwayWalaa Yehia Abdelzaher0Gomaa Mostafa-Hedeab1Haitham Ahmed Bahaa2Ahmad Mahran3Michael Atef Fawzy4Sara Mohamed Naguib Abdel Hafez5Nermeen N. Welson6Remon Roshdy Rofaeil7Department of Pharmacology, Faculty of Medicine, Minia University, Minia 61511, EgyptPharmacology Department, Medical College, Jouf University, Sakaka 11564, Saudi ArabiaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Minia University, Minia 61511, EgyptDepartment of Obstetrics and Gynecology, Faculty of Medicine, Minia University, Minia 61511, EgyptDepartment of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61511, EgyptDepartment of Histology and Cell Biology, Faculty of Medicine, Minia University, Minia 61511, EgyptDepartment of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Beni-Suef University, Beni Suef 62511, EgyptDepartment of Pharmacology, Faculty of Medicine, Minia University, Minia 61511, EgyptAims: To investigate the potential protective role of montelukast (Mont) in the pre-eclampsia rat model induced by L-NG-Nitro arginine methyl ester (L-NAME). Methods and materials: Thirty-two pregnant female albino Wistar rats were assigned to four groups: the control group: pregnant rats received vehicles; the Mont group: pregnant rats received Mont (10 mg/kg/day, p.o.) from the 6th to the 18th day of gestation; the L-NAME group: pregnant rats received L-NAME (50 mg/kg/day, i.p.) from the 9th to the 18th day of gestation; the Mont/L-NAME group: pregnant rats received Mont (10 mg/kg/day, p.o.) from the 6th to the 18th day of gestation and L-NAME (50 mg/kg/day, i.p.) from the 9th to the 18th day of gestation. Placental, hepatic, and renal malondialdehyde (MDA), total nitrites (NOx), interleukin 6 (IL-6), and tumor necrosis factor (TNF)-α were determined. Serum alanine transaminase (ALT), aspartate transaminase (AST), creatinine, urea, 24-h urinary protein, and the placental growth factor (PGF) were measured. Histopathological examinations of the placental, hepatic, and renal tissues were also performed. In addition, placental, hepatic, and renal Janus kinase 2 (Jak2) and signal transducer and activator of transcription 3 (STAT3) immunoblotting were performed. Key findings: Mont improves oxidative stress, IL-6, TNF-α, ALT, AST, creatinine, urea, 24-h urinary protein, PGF, Jak2, and STAT3 which were all affected by L-NAME. Moreover, the histopathological assessment indicated that Mont restored the normal architecture that was markedly disturbed by L-NAME. Significance: Mont exerted the biochemical and histopathological amelioration of L-NAME-caused pre-eclampsia through its anti-inflammatory, anti-oxidant function and suppression of the IL-6/Jak2/STAT3 signaling pathway.https://www.mdpi.com/1424-8247/15/8/914leukotriene receptor antagonistL-NAMEpre-eclampsiaIL-6/Jak2/STAT3 |
| spellingShingle | Walaa Yehia Abdelzaher Gomaa Mostafa-Hedeab Haitham Ahmed Bahaa Ahmad Mahran Michael Atef Fawzy Sara Mohamed Naguib Abdel Hafez Nermeen N. Welson Remon Roshdy Rofaeil Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway Pharmaceuticals leukotriene receptor antagonist L-NAME pre-eclampsia IL-6/Jak2/STAT3 |
| title | Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway |
| title_full | Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway |
| title_fullStr | Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway |
| title_full_unstemmed | Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway |
| title_short | Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway |
| title_sort | leukotriene receptor antagonist montelukast ameliorates l name induced pre eclampsia in rats through suppressing the il 6 jak2 stat3 signaling pathway |
| topic | leukotriene receptor antagonist L-NAME pre-eclampsia IL-6/Jak2/STAT3 |
| url | https://www.mdpi.com/1424-8247/15/8/914 |
| work_keys_str_mv | AT walaayehiaabdelzaher leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway AT gomaamostafahedeab leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway AT haithamahmedbahaa leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway AT ahmadmahran leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway AT michaelateffawzy leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway AT saramohamednaguibabdelhafez leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway AT nermeennwelson leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway AT remonroshdyrofaeil leukotrienereceptorantagonistmontelukastameliorateslnameinducedpreeclampsiainratsthroughsuppressingtheil6jak2stat3signalingpathway |